Compare · CVET vs MEDS
CVET vs MEDS
Side-by-side comparison of Covetrus Inc. (CVET) and TRxADE HEALTH Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVET and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CVET is the larger of the two at $2.42B, about 176.4x MEDS ($13.7M).
- MEDS has hit the wire 9 times in the past 4 weeks while CVET has been quiet.
- CVET has more recent analyst coverage (8 ratings vs 1 for MEDS).
- Company
- Covetrus Inc.
- TRxADE HEALTH Inc.
- Price
- $21.00+0.24%
- $2.67-5.15%
- Market cap
- $2.42B
- $13.7M
- 1M return
- -
- -41.96%
- 1Y return
- -
- -87.49%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 9
- Recent ratings
- 8
- 1
Covetrus Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
TRxADE HEALTH Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Latest CVET
- Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer
- Key Cannabis Exec Changes You Need To Know About: Leafly's New CCO, Glass House's New Appointment & More
- SEC Form 15-12G filed by Covetrus Inc.
- Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600
- Westlake Set To Join S&P MidCap 400, Replacing MillerKnoll; MillerKnoll To Replace Coventrus In S&P SmallCap 600
- SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)
- SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares
- SEC Form S-8 POS filed by Covetrus Inc.
- SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)
- Covetrus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Latest MEDS
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
- Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
- These Stocks Roar into October with Fresh Catalysts
- DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
- 4 Explosive Stories Enter the Investor Spotlight
- DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
- DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit